# Clinical Trials Management — World-Class Improvements

**Capability**: `pharma_ctr` | **Author**: Nyimbi Odero | **© 2025 Datacraft**

---

## 1. Adaptive Trial Design Engine

Implement response-adaptive randomisation (RAR) using a Bayesian adaptive design framework. Allow dynamic arm allocation ratios to shift based on accumulating efficacy data without compromising statistical validity. This replaces the static block randomisation stub with a full RTSM-integrated engine, supporting platform trials and basket designs.

**Regulatory basis**: FDA Adaptive Designs guidance (2019), EMA reflection paper on adaptive designs.

---

## 2. eCTD-Structured Regulatory Submission Assembly

Auto-assemble eCTD module packages (m1–m5) from TMF document references, applying agency-specific leaf mapping tables. Currently the `regulatory_submission` method produces a flat record. Replace with structured eCTD node tree generation, validating completeness against the NeeS/eCTD backbone schemas before transmission.

**Impact**: Eliminates manual assembly errors that cause submission rejections and clock stops at FDA/EMA.

---

## 3. Real-Time Safety Signal Detection via BCPNN

Integrate Bayesian Confidence Propagation Neural Network (BCPNN) IC scoring for spontaneous signal detection across the AE data store. Run after every `report_adverse_event` call. Emit structured safety signals to the `pharma_pvi` signal management capability when IC025 > 0 for a PT/drug pair.

**Reference**: WHO-UMC VigiBase methodology; ICH E2E signal management guideline.

---

## 4. CTMS ↔ EDC Bidirectional Sync

Replace the disconnected CRF data store with an async bidirectional reconciliation engine against external EDC systems (Medidata Rave, Veeva Vault, OpenClinica). Use cursor-based differential sync with field-level conflict resolution and audit trail preservation. Eliminates the dual-entry model and reduces data discrepancy rates to near-zero.

---

## 5. AI-Assisted Protocol Deviation Triage

Apply local LLM (Ollama-served Llama 3 / Mistral) to classify incoming deviation descriptions against the protocol narrative, distinguishing important vs. non-important without manual adjudication. Route important deviations directly to the IRB notification queue with pre-filled regulatory language. Reduces adjudication lag from days to minutes.

---

## 6. Stratified Patient Matching for Screen Failure Analysis

Build a patient cohort matching engine that analyses screen failures against eligibility criteria distributions using embedding similarity (MiniLM-L6 via SentenceTransformers). Identify over-restrictive criteria that disproportionately exclude historically under-recruited demographics. Feed insights to protocol amendment workflow.

**Impact**: Addresses ICH E11A paediatric extrapolation and EMA diversity requirements.

---

## 7. TMF Completeness Automation via Document Intelligence

Apply document classification models (fine-tuned LayoutLM or Donut) to uploaded TMF documents, auto-assigning ICH E6(R3) TMF Reference Model zones and artefact categories without relying on manual section specification. Flag missing essential documents against the expected TMF index for a given trial phase.

---

## 8. Site Performance Predictive Scoring

Train a lightweight gradient-boosted model on historical site-level metrics (enrolment rate, query rate, deviation frequency, monitoring visit findings) to produce a site performance risk score. Scores surface in the dashboard, enabling proactive risk-based monitoring (RBM) resource allocation aligned with ICH E6(R2) §5.18.3.

---

## 9. Automated SUSAR Narratives via NLP

Auto-generate ICH E2B(R3)-compliant SUSAR narratives from structured AE records using a local generative LLM. Include onset-to-awareness-to-report timeline, causality rationale, and supporting lab values in a structured paragraph format. Medical writer reviews rather than writes from scratch — 80% time reduction target.

---

## 10. Protocol Amendment Impact Analysis

When a new protocol version is submitted, run a semantic diff (sentence-transformer cosine distance) against the previous approved version to identify changed eligibility criteria, endpoints, and procedures. Auto-generate a re-consent impact matrix: which enrolled subjects need re-consent, which need additional assessments, which are no longer eligible.

---

## 11. Continuous Audit Trail Streaming to SIEM

Stream every audit event from `_audit()` to an Apache Kafka or MQTT topic in CE CloudEvents format instead of appending to an in-memory list. Downstream SIEM ingestion (Elastic/Splunk) provides 21 CFR Part 11 compliant electronic records with tamper-evident chaining. Replaces the current in-process list which is lost on restart.

---

## 12. Blinded Sample Size Re-estimation

Implement blinded interim sample size re-estimation (SSR) using the Cui-Hung-Wang method. Triggered at pre-specified information fractions from `interim_analysis()`. Adjusts the `target_enrollment` on the trial record without unblinding, maintaining Type I error control while allowing adaptive power maintenance.

**Regulatory basis**: EMA CHMP guidance on adaptive designs, FDA guidance (2019).

---

## 13. Supply Chain IMP Forecasting

Add an Investigational Medicinal Product (IMP) demand-forecasting module that projects site-level stock requirements from enrolment velocity and dosing schedules. Generate re-supply orders with lead time buffers. Integrate with the site close-out IMP accountability reconciliation to auto-detect discrepancies before the SCOV visit.

---

## 14. GCP Inspection Readiness Scoring

Compute a rolling GCP inspection-readiness score (0–100) from: TMF completeness %, open query age distribution, protocol deviation closure rate, monitoring visit overdue %, and AE reporting timeline compliance. Surface the score in `dashboard_summary` with a drill-down to the three highest-risk contributing factors. Modelled on TransCelerate TMF metrics.

---

## 15. Multi-Regional Regulatory Intelligence Layer

Maintain a structured regulatory intelligence database mapping each clinical indication × country to: required submission type, local authority contact, typical clock-stop risk, required local language label elements, and ICH regional appendix applicability. Expose as `get_regulatory_requirements(indication, countries)` so sponsors can plan global development programmes without manual regulatory affairs research.

---

*All improvements align with ICH E6(R3) GCP, ICH E2B(R3), ICH E3, 21 CFR Parts 11/312/314, EMA eCTD, and EMA adaptive design guidelines.*
